Association between myocarditis and other immune-related adverse events secondary to immune checkpoint inhibitor use
Avirup Guha
Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
School of Medicine, Case Western Reserve University, Cleveland, OH, USA
Search for more papers by this authorSadeer Al-Kindi
Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
School of Medicine, Case Western Reserve University, Cleveland, OH, USA
Search for more papers by this authorPrantesh Jain
School of Medicine, Case Western Reserve University, Cleveland, OH, USA
Department of Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Search for more papers by this authorNour Tashtish
Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Search for more papers by this authorChantal ElAmm
Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
School of Medicine, Case Western Reserve University, Cleveland, OH, USA
Search for more papers by this authorCorresponding Author
Guilherme H. Oliveira
Heart & Vascular Institute, University of South Florida, Tampa General Hospital & Moffitt Cancer Center, Tampa, Florida, USA
Correspondence to: Guilherme H. Oliveira, E-mail: [email protected]Search for more papers by this authorAvirup Guha
Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
School of Medicine, Case Western Reserve University, Cleveland, OH, USA
Search for more papers by this authorSadeer Al-Kindi
Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
School of Medicine, Case Western Reserve University, Cleveland, OH, USA
Search for more papers by this authorPrantesh Jain
School of Medicine, Case Western Reserve University, Cleveland, OH, USA
Department of Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Search for more papers by this authorNour Tashtish
Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Search for more papers by this authorChantal ElAmm
Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
School of Medicine, Case Western Reserve University, Cleveland, OH, USA
Search for more papers by this authorCorresponding Author
Guilherme H. Oliveira
Heart & Vascular Institute, University of South Florida, Tampa General Hospital & Moffitt Cancer Center, Tampa, Florida, USA
Correspondence to: Guilherme H. Oliveira, E-mail: [email protected]Search for more papers by this author
References
- 1Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018; 379: 2040–51.
- 2Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 2017; 377: 1345–56.
- 3Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376: 1015–26.
- 4Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540–50.
- 5Al-Kindi SG, Oliveira GH. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet 2018; 392: 382–3.
- 6Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018; 71: 1755–64.
- 7Zamami Y, Niimura T, Okada N, et al. Factors associated with immune checkpoint inhibitor-related myocarditis. JAMA Oncol 2019; 5: 1635–7.
- 8Bomze D, Hasan Ali O, Bate A, et al. Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden. JAMA Oncol 2019; 5: 1633.
- 9Neilan TG, Rothenberg ML, Amiri-Kordestani L, et al. Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. Oncologist 2018; 23: 874–8.
- 10Norwood TG, Westbrook BC, Johnson DB, et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 2017; 5: 91.
- 11Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000; 343: 1388–98.
Citing Literature
